Corcept Therapeutics Incorporated

Genentech, Inc.

Chiesi Farmaceutici S.p.a.

Pulmagen Therapeutics (inflammation) Limited

Pulmagen Therapeutics (asthma) Limited

Argenta Discovery Limited

Bayer Pharma Aktiengessellschaft

Bayer Pharma Aktiengesellschaft

F. Hoffmann-la Roche Ag

Pulmagen Therapeutics Limited

Nicholas Charles Ray

Hazel Joan Hunt

Christopher Hurley

Iain Walters

Simon Charles Goodacre

Tony Johnson

Andrew Stephen Robert Jennings

Robin D Clark

Elisabetta Armani

Monique Bodil Van Niel

Andrew Peter Cridland

Lilian Alcaraz

Terry Aaron Panchal

Jun Liang

Xiaojing Wang

Daniel Fred Ortwine

Sharada Shenvi Labadie

Birong Zhang

George Hynd

Karen Williams

Jason R Zbieg

Wei Li

Mark Edward Zak

Harry Finch

Yun-Xing Cheng

Jun M Li

Nicholas D Smith

Po-wai Yuen

Mehmet Kahraman

Steven P Govek

Johnny Yasuo Nagasawa

David Edward Clark

Rohan V Mendonca

Christine Edwards

Tao Wang

John Gary Montana

Ulf Bömer

Robert Andrew Heald

Snahel Patel

Jonathan Mark Sutton

Carmelida Capaldi

Yolanda Cancho Grande

Ulrich Bothe

Po-Wai Yuen

Judith Günther

Andiliy Gokching Lai

Martin Lange

Kwong Wah Lai

Paul M Blaney

Mohammad Sajad

Terry Kellar

Elizabeth O'Connor

Holger Siebeneicher

Reinhard Nubbemeyer

Zhiguo Liu

Holger Steuber

Horst Irlbacher

Matthew W Cartwright

Nicole Schmidt

John Wai

Jiangpeng Liao

Rosa Arienzo

Jun Li

Michael Colin Cramp

Pascal Savy

Tommy Lai

Richard James Bull

Peter H Crackett

Gwen Hickin

Trevor Keith Harrison

Mohammed Sajad

Po-Wei Yuen

Peter Crackett

Yann Griffon

Marco Van Den Heuvel

Jose Antonio Bravo

Rohan Mendonca

Jason Zbieg

John Sui-Man Wai

Elizabeth O'CONNOR

David A Clark

Paul Matthew Blaney

David Middlemiss

Yan A Griffon

Described herein are tetrahydro-pyrido[3,4-b]indol-1-yl compounds with estrogen receptor modulation activity or function having the Formula I structure:

Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof

The present invention provides heteroaryl ketone fused azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators, including their use for treating amyotrophic lateral sclerosis (ALS).

Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators

The present invention provides heteroaryl ketone fused azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators.

Described herein are tetrahydro-pyrido[3,4-b]indol-1-yl compounds with estrogen receptor modulation activity or function having the Formula I structure:  and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

Described herein are heteroaryl compounds with estrogen receptor modulation activity or function having the Formula I, II, and III structures: and

Heteroaryl estrogen receptor modulators and uses thereof

The present application relates to novel substituted indazoles, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of endometriosis and endometriosis-associated pain and other endometriosis-associated symptoms such as dysmenorrhoea, dyspareunia, dysuria and dyschezia, of lymphoma, rheumatoid arthritis, spondyloarthritis (especially psoriatic spondyloarthritis and Bekhterev's disease), lupus erythematosus, multiple sclerosis, macular degeneration, COPD, gout, fatty liver disorders, insulin resistance, neoplastic disorders and psoriasis.

2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs

Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

Heterocyclic estrogen receptor modulators and uses thereof

Described herein are tetrahydro-pyrido[3,4-b]indol-1-yl compounds with estrogen receptor modulation activity or function having the Formula I structure: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

Compounds of Formula 0, Formula I and Formula II and methods of use as Janus kinase inhibitors are described herein.

Triazolopyridine compounds, compositions and methods of use thereof

Described herein are compounds that are estrogen receptor modulators of Formula (I): 

Estrogen receptor modulators and uses thereof

Growing community of inventors

Harlow, United Kingdom

Nicholas Charles Ray